ECM

Brief IPOs & Placements: Wuxi Biologics Placement – Past Deals Have Done Well but Progressive Returns Are Getting Lower and more

In this briefing:

  1. Wuxi Biologics Placement – Past Deals Have Done Well but Progressive Returns Are Getting Lower
  2. Ruhnn (如涵) Pre-IPO Review- Significant Concentration Risk
  3. Frontage Holding (方达控股) IPO: Updates from 2018 Numbers
  4. Tencent Music 4Q18 Quick Note – Growth on Track, Margins Could Drag – Stock Price Needs a Breather
  5. Lyft IPO: Valuation Analysis (Prudent Investment or Quasi-Gambling?)

1. Wuxi Biologics Placement – Past Deals Have Done Well but Progressive Returns Are Getting Lower

Placement%20specifics

Biologics holdings is looking to raise upto US$517m by selling a 4.2% stake in Wuxi Biologics (Cayman) Inc (2269 HK). This will be fourth placement by the company since it listed less than two years ago. Below is a link to our coverage of the listing and the earlier placement:

Each of the past placement has been of a similar size and has generally done well. The company recently reported results which were ahead of street estimates. The deal scores a marginal positive score on our framework but there is still a lot more selling left once the 90-day lock-up expires.

2. Ruhnn (如涵) Pre-IPO Review- Significant Concentration Risk

Inventory%20write%20down

Ruhnn Holding Ltd (RUHN US) is looking to raise about US$200m in its upcoming IPO.

The company is an internet key opinion leader (KOL) incubator in China. Revenue and GMV grew at impressive rates of 63% and 57% YoY in FY2018, respectively.

The idea of being able to leverage on KOLs influence over consumers to understand demand and retain consumers is interesting but Ruhnn has yet to demonstrate that it has a sustainable business model. 

Gross margin has deteriorated and losses widened as a percentage of revenue. Service fee paid to KOLs as a percentage of revenue has increased and showed little improvement in 9M FY2019.  The company depends heavily on the top KOL, Zhang Dayi, to generate revenue, almost half of the company’s GMV and revenue is generated from her.

3. Frontage Holding (方达控股) IPO: Updates from 2018 Numbers

Profit%20adjustment

Frontage Holding, a contract research organization subsidiary of A-share listed Hangzhou Tigermed Consulting (300347 CH), re-filed to list on the Hong Kong Stock Exchange recently. We have covered the company’s fundamentals in our previous insight here. In this insight, we will provide an updated analysis based on new data available from the new prospectus, as well as our thoughts on valuation.

4. Tencent Music 4Q18 Quick Note – Growth on Track, Margins Could Drag – Stock Price Needs a Breather

Estimates%20quarterly%20as%20of%2018th%20mar

Tencent Music Entertainment (TME US) reported its full year results today, post US market close. Revenue growth was slightly ahead of estimates as paying ratio continue to improve for both online music (subscription revenue) and social entertainment (live streaming). Growth for the latter continued to be driven more by ARPU rather than user growth. 

The concerning bit in the results was the decline in gross margins as the company continues to invest in more content. 

My previous insights on TME’s IPO:

5. Lyft IPO: Valuation Analysis (Prudent Investment or Quasi-Gambling?)

Lyft 1a

Our base case forecast is Case 2 (among three scenarios analysis), which suggests an implied market cap of $21 billion or $75 per share. Given that our intrinsic value of the company does not provide enough upside versus the likely IPO price, we would AVOID this deal. 

Even if the company is able to complete this IPO, raising nearly $2.0-2.5 billion, it is very possible that the company may need to come back to the market in two or three years in a secondary share offering, which would dilute the existing shareholders. This is probably the biggest risk I see with the Lyft IPO right now. 

Our base case financial forecast for Lyft assumes the following:

  • Sales growth rate (CAGR from 2018 to 2030) – 26.6%
  • Year in which Lyft turns operating profit positive – 2025
  • Operating margin in 2030 – 15.0%

Get Straight to the Source on Smartkarma

Smartkarma supports the world’s leading investors with high-quality, timely, and actionable Insights. Subscribe now for unlimited access, or request a demo below.